Compare RMNI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMNI | HELP |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.1M | 279.9M |
| IPO Year | 2015 | N/A |
| Metric | RMNI | HELP |
|---|---|---|
| Price | $3.94 | $5.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.00 | ★ $51.50 |
| AVG Volume (30 Days) | 406.9K | ★ 1.5M |
| Earning Date | 04-30-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 197.50 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $431,496,000.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | $388.50 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $2.87 | $4.29 |
| 52 Week High | $5.38 | $8.55 |
| Indicator | RMNI | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 49.69 |
| Support Level | $3.91 | $4.63 |
| Resistance Level | $4.15 | $6.26 |
| Average True Range (ATR) | 0.14 | 0.50 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 74.85 | 34.43 |
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.